UNC93B2: Potential Drug Target and Biomarker (G641922)

Target Name: UNC93B2

NCBI ID: G641922

UNC93B2

Other Name(s): UNC93B2P | unc-93 homolog B2 (pseudogene) | Unc-93 homolog B2 pseudogene (C. elegans)

UNC93B2: Potential Drug Target and Biomarker

UNC93B2 (UNC93B2P) is a protein that is expressed in various tissues of the body, including the brain, heart, liver, and pancreas. It is a member of the UNC93 family of proteins, which are known for their role in cell signaling and inflammation.

UNC93B2 has been shown to play a role in a variety of biological processes, including the regulation of cell growth, differentiation, and survival. It has also been shown to be involved in the development and progression of various diseases, including cancer.

One of the most promising aspects of UNC93B2 is its potential as a drug target. Researchers have identified several potential binding sites on UNC93B2 that could be targeted by small molecules, making it a promising target for drug development.

In addition to its potential as a drug target, UNC93B2 has also been shown to be a potential biomarker for several diseases. For example, studies have shown that UNC93B2 is expressed abnormally in the brains of individuals with Alzheimer's disease, and that it is involved in the development of certain cancer types.

Overall, UNC93B2 is a protein that has the potential to be a valuable drug target and biomarker for a variety of diseases. Further research is needed to fully understand its role in these processes and to develop effective treatments.

Protein Name: Unc-93 Homolog B2 (pseudogene)

The "UNC93B2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about UNC93B2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets